For most of us, the growing evidence that the efficacy of COVID-19 vaccines is declining over time should be a cause of worry. For the drug companies that have spent billions of dollars developing them, it’s a once-in-a-lifetime opportunity.
Recent studies on vaccine effectiveness have led to a run of orders for boosters in recent weeks. The U.S. will start distributing extra shots beginning Sept. 20th and expects to roll out about 100 million doses in the coming months.
Unable to view this article?
This could be due to a conflict with your ad-blocking or security software.
Please add japantimes.co.jp and piano.io to your list of allowed sites.
If this does not resolve the issue or you are unable to add the domains to your allowlist, please see this support page.
We humbly apologize for the inconvenience.
In a time of both misinformation and too much information, quality journalism is more crucial than ever.
By subscribing, you can help us get the story right.
SUBSCRIBE NOW
PHOTO GALLERY (CLICK TO ENLARGE)
With your current subscription plan you can comment on stories. However, before writing your first comment, please create a display name in the Profile section of your subscriber account page.